Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
5
Neutral
2
Bullish
7
Bearish
36
Neutral
2
Bullish
8
Bearish
31
Neutral
0
Bullish
1
Discovery themes featuring this stock
Rossari Biotech Limited is a leading manufacturer of specialty chemicals, offering sustainable chemical solutions across various industries including HPPC, TSC, and AHN.
The company reported a 13% year-on-year revenue growth for Q3 FY26, driven by strong performance in international markets and steady growth across its core business segments.
Rossari has recently received board approval to establish a new greenfield manufacturing facility in Saudi Arabia, aimed at enhancing its global supply chain capabilities and expanding its international footprint.
Despite ongoing investments and capacity expansion efforts, Rossari maintains a solid financial structure with healthy liquidity, facilitating continued strategic growth initiatives.
The company's focus on R&D and innovation is evident in the introduction of new environmentally benign chemical solutions and strategic acquisitions to enhance its product portfolio.
Chemicals & Petrochemicals
Specialty Chemicals
2,710 Cr
High Risk
18.0
44.1
1.6
2.0
728.75
372.90
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
121.83 | 3,032 Cr | 15.17 | 2.80 | 3.28 | 16.63 | 22.86 | 15.55 | ||
277.25 | 2,851 Cr | 14.13 | 2.81 | 0.64 | 19.92 | 28.27 | 13.98 | ||
1843.00 | 2,804 Cr | 21.50 | 6.10 | 0.00 | 27.80 | 34.27 | 13.67 | ||
489.00 | 2,710 Cr | 17.98 | 2.03 | 0.10 | 11.19 | 13.06 | 6.59 | ||
161.70 | 2,675 Cr | 58.03 | 1.51 | 0.94 | 3.14 | 4.35 | 2.64 | ||
125.30 | 2,395 Cr | 65.63 | 2.31 | 0.00 | 1.18 | 3.77 | 1.01 | ||
141.55 | 1,939 Cr | 39.69 | 1.42 | 0.71 | 3.60 | 5.52 | 2.37 | ||
| Median: 7 Co. | — | 161.70 | 2,710 Cr | 21.50 | 2.31 | 0.64 | 11.19 | 13.06 | 6.59 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Rossari Biotech Ltd (ROSSARI) is currently trading at 489.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Rossari Biotech Limited is a leading manufacturer of specialty chemicals, offering sustainable chemical solutions across various industries including HPPC, TSC, and AHN. The company reported a 13% year-on-year revenue growth for Q3 FY26, driven by strong performance in international markets and steady growth across its core business segments. Rossari has recently received board approval to establish a new greenfield manufacturing facility in Saudi Arabia, aimed at enhancing its global supply chain capabilities and expanding its international footprint. Despite ongoing investments and capacity expansion efforts, Rossari maintains a solid financial structure with healthy liquidity, facilitating continued strategic growth initiatives. The company's focus on R&D and innovation is evident in the introduction of new environmentally benign chemical solutions and strategic acquisitions to enhance its product portfolio.
Over the past 52 weeks, Rossari Biotech Ltd has traded between a low of ₹372.90 and a high of ₹728.75. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Rossari Biotech Ltd has a market capitalization of approximately 2,710.43. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Rossari Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 17.98 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 2,710.43 Cr, Rossari Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Rossari Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Rossari Biotech Ltd is 17.98. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Total revenues were ₹2,095.2 crore (₹20,952 million) in FY25, up 13.6% from ₹1,844.7 crore (₹18,447 million) in FY24.
The board meeting was scheduled for January 17, 2026 at 12:30 PM IST to consider unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2025.
Earnings Call/Transcript
Rossari Biotech Ltd informs that the transcript of its Q1 FY27 earnings conference call held on 2026-07-20 is enclosed and available on the company's website at www.rossari.com/announcement.
Earnings Call/Transcript
Rossari Biotech filed the transcript of its Q1 FY27 earnings conference call held on 2026-07-20; transcript is available on the company's website under Investor Call/Announcements.
AGM/EGM Notice
Rossari Biotech Ltd: Outcome of 17th AGM held on 2026-07-20. All resolutions passed including adoption of audited financials, declaration of dividend and appointment of director; consolidated scrutinizer's report and voting results attached.
AGM/EGM Notice
Rossari Biotech Ltd held its 17th AGM on 2026-07-20 via VC; all resolutions (including adoption of standalone and consolidated FY2025-26 accounts and declaration of dividend) were passed. Voting results and consolidated scrutinizer's report enclosed.
AGM/EGM Notice
Rossari Biotech Ltd held its 17th AGM on 2026-07-20. All resolutions were passed, including adoption of audited standalone and consolidated financials and declaration of dividend. Voting results and scrutinizer's report enclosed and available online.
AGM/EGM Notice
Rossari Biotech announced the outcome of its 17th AGM held on 2026-07-20; all resolutions were passed, including adoption of audited standalone and consolidated financials and declaration of dividend. Voting results and scrutinizer's report enclosed.
